Understanding vaccine development
|
|
- Gyles O’Connor’
- 6 years ago
- Views:
Transcription
1 Understanding vaccine development Firdausi Qadri Director, Centre for Vaccine Sciences International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
2 Outline of this talk 1. Understanding disease burden and the need for vaccines 2. Different stages of development of vaccines 3. Funding, risks and challenges
3 Understanding need for vaccines Knowledge of natural history of infection and the spectrum of illness Information on incidence or prevalence of the infectious disease in consideration Disease burden data- Although disease may be prevalent, accurate data on burden of disease may be missing due to lack of surveillance at country level
4 Vaccine Development Laboratory and animal studies Exploratory stage- basic and applied research on vaccine components, protective antigen and host responses Pre-clinical stage- animal experimentation to determine mode of action, route of administration, protection, dosage Availability of existing animal model and a correlate of protection can accelerate vaccine development
5 Studies in human participants Phase I- Safety and immunogenicity trials on relatively limited number of participants (1-2 yr: n=20-80) Human Challenge studies (2-3yr: n=10-30) Moving to larger Phase II studies (2-3 yr: n= ) Phase III, protective efficacy trials (3-5 yr: n= ,000) Licensure and WHO prequalification (1-2 yr) Phase IV effectiveness studies (2-4 yr) Commercialization and marketing (variable) Post marketing surveillance and more clinical studies This path can take 10 years for vaccines needed for mid level to high income countries: when targeted for low income countries the process may get delayed to over years or even over 100 years
6 Cost of development of vaccines Research and discovery to product registration may cost $200m-500m Commercial realities have reduced private investment developing country spending is low but increasingly supported by funding from industrialized countries including public and private foundations Research and development requires industrial partner and manufacturer to decrease capital investment costs and for need to produce vaccines in accordance with good manufacturing practices
7 What are the risks involved in vaccine development? it is a lengthy and complex procedure with many risks many preclinical and Phase I-III studies on vaccines do not result in a registered vaccine the probability of preclinical vaccine reaching market have a 5:1 odds of success ; that is for every vaccine marketed there should be 4-5 vaccines under development added to this is the political/economic issues and uncertainties in end-consumer use Serdobova and Kieny, 2006
8 Other challenges faced in development of vaccines Vaccines may not be equally efficacious in all settings Not enough known about vaccine composition, dosage and immunization schemes for developing country populations immunogenicity and protection can be lower in malnourished populations Negative effect of concomitant infection on vaccine take rates- TB, HIV, malaria, enteric infections Primed versus naïve or children versus adult responses can be different In country and local production of vaccines may be hindered by lack of regulatory authorities leading to delay in WHO prequalification and availability
9 Conclusions and the way forward Vaccine development and production need to be enhanced Basic research and understanding of region and country specific needs for composition of vaccines and related host responses Developing country producers need to be encouraged to enhance capacity with funding and technology transfer support This can boost vaccine usage regional and country specific vaccine candidates efficacious shipment costs requirement of cold room storage capacity Can result in savings to both GAVI and country funds and accelerate access to appropriate products for diverse populations to meet MDG goals
Developing a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationThe WHO END-TB Strategy
ENDING TB and MDR-TB The WHO END-TB Strategy Dr Mario RAVIGLIONE Director Joint GDI/GLI Partners Forum WHO Geneva, 27 April 2015 This talk will deal with TB Burden Progress, Challenges Way Forward Who
More informationFinancing Influenza Vaccine R&D
Financing Influenza Vaccine R&D WHO GAP-II Geneve, Switzerland July 13, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary & Director HHS/ASPR/BARDA 0 Vaccine Development is Risky, Lengthy, & Expensive
More informationDeveloping a novel Group B Streptococcus (GBS) Vaccine. Patrick Tippoo
Developing a novel Group B Streptococcus (GBS) Vaccine Patrick Tippoo Presentation 1. Overview of Biovac 2. GBS Project Overview 3. African Significance Biovac Overview A Centre of Excellence rooted in
More informationMedical Innovation changing business model. Marie-Paule Kieny, WHO-WIPO-WTO, 5 July 2013
Medical Innovation changing business model Marie-Paule Kieny, WHO-WIPO-WTO, 5 July 2013 The Meningitis Vaccine Project (MVP) A successful vaccine development for Africa, partnering with a DCVM An exemplary
More informationProcurement Strategy for Rotavirus and Pneumococcal Conjugate Vaccines. Supplier meeting UNICEF Supply Division 3-4 April 2008 Ann Ottosen
Procurement Strategy for Rotavirus and Pneumococcal Conjugate Vaccines Supplier meeting Supply Division 3-4 April 2008 Ann Ottosen Strategic decisions leading to procurement of Rotavirus and Pneumococcal
More informationGAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment
GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment Tania Cernuschi Third Regional Pneumococcal Symposium, Istanbul, 13th - 14th February 2008 1 The GAVI Alliance Public-private
More informationRSV vaccine research and development: WHO technical roadmap
RSV vaccine research and development: WHO technical roadmap Johan Vekemans (MD, PhD) WHO Initiative for Vaccine Research Washington, 18 th December 2017 What is WHO s Initiative for Vaccine Research (IVR)
More informationIVI STRATEGY ARTICULATION. October 12, 2015
IVI STRATEGY ARTICULATION October 12, 2015 Overall messages for today Our Vision and Mission are as relevant today as they have ever been We need to focus on the diseases and activities where we can have
More informationMedia Coverage World Health Organisation Grants Prequalification to Bharat Biotech s rotavirus vaccine, ROTAVAC(R)
Media Coverage World Health Organisation Grants Prequalification to Bharat Biotech s rotavirus vaccine, ROTAVAC(R) 1) Business Wire World Health Organization Grants Prequalification to Bharat Biotech s
More informationGAVI, THE VACCINE ALLIANCE
#vaccineswork GAVI, THE VACCINE ALLIANCE Partnerships for Health Outcomes Susan Brown July, 2017, New York Gavi/2012/Doune Porter www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and
More informationInvesting for Impact
Global Fund Strategic Framework: Investing for Impact M&E: Capturing data to improve services Workshop to Scale Up the Implementation of Collaborative TB/HIV Activities in Africa 10-11 April, 2013; Maputo,
More informationGlobal health and vaccination: TB & beyond. Dr Mary Moran Executive Director
Global health and vaccination: TB & beyond Dr Mary Moran Executive Director mmoran@policycures.org Outline About Policy Cures 3 reasons to focus on vaccine innovation Where are we today? The pipeline Where
More informationBeyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective
Beyond vaccine introduction: Working together for sustainable, resilient immunization programs Manufacturer perspective IAIM Regional Meeting for the Americas and Europe 1 February 2017 Anupama Tantri
More informationHPV Vaccination. Dr. Vivien Tsu PATH. HPV Vaccination 1
HPV Vaccination Dr. Vivien Tsu PATH HPV Vaccination 1 HPV vaccine overview 1 First vaccines to focus on a female cancer. Prepared from virus-like particles (VLPs). VLPs are non-infectious. Two vaccines
More informationNational Health & Medical Research Council (NHMRC) Results Fellowships and Australia/European Union Collaborative Grants Scheme 2018
National Health & Medical Research Council (NHMRC) Results Fellowships and Australia/European Union Collaborative Grants Scheme 2018 The NHMRC has publically released results (embargo lifted on 11 October
More informationMaternal Influenza Immunization at WHO
Maternal Influenza Immunization at WHO Dr. Justin R. Ortiz Medical Officer Initiative for Vaccine Research GAP Partners Meeting Dubai, UAE 26 March 2014 WHO Position Paper Mother s Gift Trial GAVI Review
More informationThe Expanding Rotavirus Vaccine Landscape: Lessons learned from Influenza Vaccines
The Expanding Rotavirus Vaccine Landscape: Lessons learned from Influenza Vaccines Kathleen Neuzil, MD, MPH Director, Center for Vaccine Development University of Maryland School of Medicine September
More informationThe Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative
The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and
More informationGian Gandhi. Vaccine Pre tender Meeting UNICEF Supply Division
An Advance Market Commitment for new vaccines The Pneumococcal Pilot Gian Gandhi GAVI Alliance Vaccine Pre tender Meeting UNICEF Supply Division Copenhagen, 10 December 2008 2 Objectives ofthepresentation
More informationTarget Product Profile and Technical Requirements for Conjugated Pneumococcal Vaccines. AMC Pre-tender meeting. Copenhagen 10 March 2011
Target Product Profile and Technical Requirements for Conjugated Pneumococcal Vaccines 1 Target Product Profile for AMC support The specifications relate to the public health impact and suitability of
More informationMaternal Immunization: Unique considerations of public health value of vaccines given to pregnant women
Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Estimating the full public health value of vaccines Kathleen M. Neuzil, MD, MPH Professor of Medicine
More informationTB Vaccine Development Strategy Overview
TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the
More informationEstimating TB burden. Philippe Glaziou World Health Organization Accra, Ghana
Estimating TB burden Philippe Glaziou World Health Organization Accra, Ghana Outline Basic facts about TB epidemiology What should we expect with regards TB burden over time? Main indicators of TB disease
More informationClinical trials: Role of a DSMB
Clinical trials: Role of a DSMB 15 th Advanced Course of Vaccinology May 15, 2014 Penny M. Heaton, MD Director of Vaccine Development Vaccine Development: Catalyze development of low cost vaccines that
More informationCOMBINATION VACCINES: HOW AND WHY? LESSONS LEARNED.
COMBINATION VACCINES: HOW AND WHY? LESSONS LEARNED. Global Vaccine and Immunization Research Forum Johannesburg, March 16, 2016 Michel De Wilde, MDWConsultant, LLC STRONG RATIONALE EXISTS FOR COMBINATION
More informationA NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT. Introducing the Gates Medical Research Institute
A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT Introducing the Gates Medical Research Institute MY JOURNEY A NEW PARADIGM FOR TRANSLATIONAL VACCINE DEVELOPMENT Introducing the Gates Medical Research
More informationHilleman Laboratories
Hilleman Laboratories If I had to name a person who has done more for the benefit of human health, with less recognition than anyone else, it would be Maurice Hilleman. Maurice should be recognized as
More informationThe Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
More informationUNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013
UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013 Presentation overview Scope of UNICEF procurement Overview of UNICEF procurement Vaccine market updates UNICEF procures
More informationAssembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World
Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World Irina Serdobova, MBA, PhD, and Marie-Paule Kieny, PhD Commercial realities have drastically reduced private
More informationIn the Name of God, the Compassionate, the Merciful. Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION.
In the Name of God, the Compassionate, the Merciful Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION on the FIRST EMIRATES INTERNATIONAL CONFERENCE ON VACCINATION Dubai,
More informationEncouraging Partnership and Collaboration for Success in the Field of R&D for Global Health
Encouraging Partnership and Collaboration for Success in the Field of R&D for Global Health Fil Randazzo, Ph.D. Deputy Director Global Health Discovery & Translational Sciences EVERY PERSON DESERVES THE
More informationUpdate on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014
Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating
More informationPerspectives on Ensuring Access to Vaccines in Lower Income Countries
Perspectives on Ensuring Access to Vaccines in Lower Income Countries Greg Widmyer Deputy Director, Vaccine Delivery Foundation Merieux January 20, 2015 Bill & Melinda Gates Foundation BMGF GLOBAL PROGRAMS
More informationDiagnostics product development projects
Page 0 Diagnostics product development projects Smiljka de Lussigny Technical Officer, HIV UNITAID Copenhagen, 23 September 2013 Page 1 1 2 3 About UNITAID HIV diagnostics market UNITAID s current investment
More informationTALKING POINTS INTRODUCTION
TALKING POINTS INTRODUCTION I have been asked by Amina to talk about health and development and to share some of the experiences of the GAVI Alliance model that might be replicated in furtherance of other
More information1. The World Bank-GAVI Partnership and the Purpose of the Review
1. The World Bank-GAVI Partnership and the Purpose of the Review 1.1 The new World Bank Group strategy makes a strong case for an expanded World Bank Group role in global and regional dialogue and collective
More informationWHO Preferred Product Characteristics for RSV Vaccines
WHO Preferred Product Characteristics for RSV Vaccines 1 TABLE OF CONTENTS I. Introduction 3 II. Context of available interventions 3 III. WHO strategic vision for RSV vaccines 4 IV. RSV vaccines for maternal
More informationRegulatory requirements for universal flu vaccines Perspective from the EU regulators
Regulatory requirements for universal flu vaccines Perspective from the EU regulators EDUFLUVAC workshop 12-14 June Marco Cavaleri Head of Anti-infectives and Vaccines Scientific & Regulatory Management
More informationAdvancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction
Advancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction Despite significant advances in child survival, deaths in the earliest
More informationEbola Vaccines and Vaccination
Ebola Vaccines and Vaccination Report of the SAGE Working Group on Ebola Vaccines and Vaccination with provisional recommendations for vaccination September 30, 2015 SECTION C: CONCLUSIONS AND RECOMMENDATIONS
More informationReport to the. GAVI Alliance Board November 2013
Report to the GAVI Alliance Board 21-22 November 2013 Subject: Report of: Authored by: Agenda item: Category: Consent Agenda: Opening of Funding Window for Japanese Encephalitis Hind Khatib-Othman, Managing
More informationBurden of Disease Research Unit Understanding the Burden of Disease and Health Inequalities in South Africa
Burden of Disease Research Unit Understanding the Burden of Disease and Health Inequalities in South Africa Dr Debbie Bradshaw Outline Socio-economic conditions in South Africa Burden of disease Inequalities
More informationThe Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework
The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework A position paper from the Directors of the GISRS WHO Collaborating
More informationRegulatory Considerations for Determining Vaccine Efficacy U.S. FDA Perspective
Regulatory Considerations for Determining Vaccine Efficacy U.S. FDA Perspective Marion Gruber, PhD. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research Food and Drug
More informationPROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE
PROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE Gerald R. Kovacs, PhD Director, Division of Chem/Bio/Rad/Nuc Medical Countermeasures Biomedical Advanced Research and Development Authority Assistant
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationStandardization for Preclinical Evaluation of Influenza Vaccines in Animal Models - WHO activities
Standardization for Preclinical Evaluation of Influenza Vaccines in Animal Models - WHO activities 2 nd WHO Integrated Meeting on development and clinical trials of Influenza vaccines that induce broadly
More informationHerd Protective Effects of Vaccines. John Clemens icddr,b, Dhaka, Bangladesh
Herd Protective Effects of Vaccines John Clemens icddr,b, Dhaka, Bangladesh Promising Vaccine Candidate Phase I. Safe and Immunogenic in Healthy Adults? Yes No Phase II. Safe and Immunogenic in the Target
More informationSTI vaccines are a major priority for sustainable global STI control. Large number of infections globally
Brisbane, 4 Sept 05 STI are a major priority for sustainable global STI control Preliminary WHO estimates: 357 million new cases of curable STIs in 0 The global roadmap for STI : Moving forward Large number
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationOraSure Technologies. JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014
OraSure Technologies JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE June 4, 2014 Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including
More informationMY DISSERTATION PROCESS & EFFECTIVENESS OF ROTAVIRUS VACCINES IN LOW- INCOME SETTINGS
MY DISSERTATION PROCESS & EFFECTIVENESS OF ROTAVIRUS VACCINES IN LOW- INCOME SETTINGS MARCH 3, 2017 LAUREN M. SCHWARTZ, MSPH PHD CANDIDATE LAURENMS@UW.EDU OUTLINE FOR TODAY What do you want to get out
More information5th Meeting of the Initiative against Diarrheal & Enteric diseases in Asia IDEA
5th Meeting of the Initiative against Diarrheal & Enteric diseases in Asia IDEA Firdausi Qadri icddr,b Country Situation Update: Bangladesh Hanoi, Vietnam 7th March 2017 1 [Insert presentation title] 2
More informationThe power of partnership: the GAVI Alliance Board
The power of partnership: the GAVI Alliance Board 1 GAVI s mission To save children s lives and protect people s health by increasing access to immunisation in poor countries Strategic goals 2011 2015!
More informationVaccine Innovation and Adult Immunization Landscape
Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org
More informationHIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES
More informationVaccine Development in the Developing World; past, present and future: SEAR Perspective
Speech by Dr Samlee Plianbangchang Regional Director, WHO South-East Asia Vaccine Development in the Developing World; past, present and future: SEAR Perspective 15 June 2010 Bangkok, Thailand Vaccine
More informationWhy does Diarrhea matter? PREVENTING MORE THAN ONE MILLION UNNECESSARY DEATHS EVERY YEAR
Why does Diarrhea matter? PREVENTING MORE THAN ONE MILLION UNNECESSARY DEATHS EVERY YEAR Presentation made at CORE GROUP on February 16, 2012 Dyness Kasungami, Child Health Team Leader, MCHIP Presentation
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationGlobalization & its Impact on Youth Health in Asia. Cai Cai Social Affairs Officer Health and Development Section Emerging Social Issues Division
Globalization & its Impact on Youth Health in Asia Cai Cai Social Affairs Officer Health and Development Section Emerging Social Issues Division Globalization -openness, cross-border flows, -Rules & institutions
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationBangladesh Resource Mobilization and Sustainability in the HNP Sector
Bangladesh Resource Mobilization and Sustainability in the HNP Sector Presented by Dr. Khandakar Mosharraf Hossain Minister for Health and Family Welfare Government of the People's Republic of Bangladesh
More informationHepatitis A. Rabies and. Seasonal Influenza Vaccines Vaccine Industry Consultation October 2018
Hepatitis A Rabies and Seasonal Influenza Vaccines 2018 Vaccine Industry Consultation October 2018 Presentation overview Hepatitis A vaccine Rabies Vaccine Seasonal Influenza Vaccine Introduction: Hepatitis
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationManaging cost considerations and access to technology for cost effective vaccine manufacture in developing countries.
Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities
More informationEconomics of Vaccine Development A Vaccine Manufacturer s Perspective
Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria
More informationA Briefing Paper on Rotavirus
COMMON VIRUS AND SENSELESS KILLER: A Briefing Paper on Rotavirus DIARRHEA KILLS. MOTHERS IN THE WORLD S POOREST COUNTRIES KNOW THIS ALL TOO WELL. It s a fact few people in wealthier nations realize. Rotavirus
More informationEC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
More informationUpdating the Malaria Vaccine Technology Roadmap
Updating the Malaria Vaccine Technology Roadmap Vasee Moorthy MRCP PhD MPAC 14 March 2013 Purpose of this MPAC session MPAC to be updated on the strategic R&D framework for malaria vaccines, including
More informationWorking for an International Organization in Public-Private Partnership : The Global Fund to Fight AIDS, Tuberculosis and Malaria
Working for an International Organization in Public-Private Partnership : The Global Fund to Fight AIDS, Tuberculosis and Malaria Birgit Poniatowski Acting Manager, Board Relations Overview The Global
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationVaccination in acute humanitarian emergencies
Vaccination in acute humanitarian emergencies Guidance on the choice of vaccines and implementation of vaccination and update on the issue of access to vaccines. Report of Vaccination in Humanitarian Emergency
More informationResolution adopted by the General Assembly. [without reference to a Main Committee (A/62/L.39 and Add.1)]
United Nations General Assembly Distr.: General 7 March 2008 Sixty-second session Agenda item 47 Resolution adopted by the General Assembly [without reference to a Main Committee (A/62/L.39 and Add.1)]
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationImproving access to medicines for patients in lower-income countries
Improving access to medicines for patients in lower-income countries AHBS II Dakar November 6, 2017 Our access strategy: tailoring our approach to income segments Income segments 1 High Income Upper-middle
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationAhimsa Roundtable Cape Town, South Africa June 2015
A partnership to save lives The critical role of faith-based organizations and faith-inspired communities in Global Health and the fight against AIDS, TB and malaria Ahimsa Roundtable Cape Town, South
More informationThe Sustainable Development Goals: The implications for health post Ties Boerma, Director of Information, Evidence and Research, WHO, Geneva
The Sustainable Development Goals: The implications for health post-2015 Ties Boerma, Director of Information, Evidence and Research, WHO, Geneva Outline SDGs: general process and features 2030 Agenda:
More informationUpdates on Typhoid Conjugate vaccine Development: IVI
Updates on Typhoid Conjugate vaccine Development: IVI Sushant Sahastrabuddhe 8 th International Conference on Typhoid Fever and Other Invasive Salmonelloses 2 nd March 2013 Outline of the presentation
More informationNew vaccine technologies: Promising advances may save more lives
New vaccine technologies: Promising advances may save more lives Vaccine Technology III June 10, 2010 PATH s vision A world where innovation ensures that health is within reach for everyone. 2 PATH s mission
More informationOverall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
More informationMedia Contact: Amy Rose Media Contact: Shelley Ducker (908) (240) (908)
FOR IMMEDIATE RELEASE News Release Merck contacts: QIAGEN contacts: Media Contact: Amy Rose Media Contact: Shelley Ducker (908) 423-6537 (240) 686-7603 Investor Contact: Eva Boratto Investor Contact: Solveigh
More informationHarnessing the power of vaccines using the public and private sector: A 21 st century model for international development
Harnessing the power of vaccines using the public and private sector: A 21 st century model for international development Dr. Seth Berkley, CEO GAVI Alliance Wellcome Trust Cambridge Centre for Global
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationSafe Injection Equipment
Safe Injection Equipment Industry Consultation 28 th 29 th March 2017 Overview of UNICEF procurement of Safe Injection Equipment Rob Matthews, HTC Objective of Session Provide an overview of UNICEFs engagement
More informationWHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES
WHO VACCINE SUPPLY & QUALITY SUPPORT FOR NATIONAL IMMUNIZATION PROGRAMMES Immunization and vaccine development in the last decade Since the Millennium Summit in 2000, immunization substantial international
More informationREGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC. second edition
REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC second edition World Health Organization 2014 The designations employed and the presentation of the material in
More informationTHE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability
THE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability International Federation of Pharmaceutical Manufacturers & Associations THE COMPLEX JOURNEY
More informationMY DISSERTATION PROCESS & EFFECTIVENESS OF ROTAVIRUS VACCINES IN LOW- INCOME SETTINGS
MY DISSERTATION PROCESS & EFFECTIVENESS OF ROTAVIRUS VACCINES IN LOW- INCOME SETTINGS MARCH 2, 2018 LAUREN M. SCHWARTZ, MSPH PHD CANDIDATE LAURENMS@UW.EDU OUTLINE FOR TODAY What do you want out of your
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationCommon Virus and Senseless Killer: A Briefing Paper on Rotavirus
Common Virus and Senseless Killer: A Briefing Paper on Rotavirus Diarrhea kills. Mothers in the world s poorest countries know this all too well. It s a fact few people in wealthier nations realize. Rotavirus
More informationNew Tuberculosis Vaccines Developmental Strategies
New Tuberculosis Vaccines Developmental Strategies Michael Brennan, Ph.D. Aeras SAGE Geneva, Switzerland 10 November 2011 The Potential of New TB Vaccines A new, more effective TB vaccine could: Be safer
More informationBeyond effectiveness: research on vaccines seen as a continuum
Beyond effectiveness: research on vaccines seen as a continuum Alejandro Cravioto, MD, PhD Facultad de Medicina, Universidad Nacional Autónoma de México Chair, Strategic Advisory Group of Experts (SAGE)
More informationProduct Development for Vaccines Advisory Committee:
Product Development for Vaccines Advisory Committee: Highlights from the 2016 year of vaccine development SAGE, October 2016 David C. Kaslow, MD Chair, Product Development for Vaccines Advisory Committee
More information1201 Maryland Avenue SW Suite 900 Washington, DC
June 14, 2012 Lonnie King, D.V.M. Chair Committee on Identifying and Prioritizing New Preventive Vaccines for Development Institute of Medicine 500 Fifth Street, NW Washington, DC 20001 Re: Ranking Vaccines:
More informationMathematical Models for the Control of Infectious Diseases With Vaccines
Mathematical Models for the Control of Infectious Diseases With Vaccines Ira Longini Department of Biostatistics and Center for Statistical and Quantitative Infectious Diseases (CSQUID), University of
More informationFrom Vaccine Development to Policy: A Brief Review of WHO Vaccine-Related Activities and Advisory Processes (2017)
1. Introduction From Vaccine Development to Policy: A Brief Review of WHO Vaccine-Related Activities and Advisory Processes (2017) To help achieve the implementation of the Global Vaccine Action Plan (GVAP),
More information